Condition: Amyloid Cardiomyopathy · Sponsor: Seoul St. Mary's Hospital
This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.
This description comes directly from the study's public registry record.
Jong-Chan Youn, MD, PhD · 82-2-3147-9853 · jong.chan.youn@gmail.com
Maljoung Ahn, RN · 82-2-3147-9853 · cmccasc@gmail.com
Always discuss trial participation with your own doctor first.
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Seoul St. Mary's Hospital, The Catholic University of Korea | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07240844